Group 1 - Hubei Yihua (SZ 000422) held its 54th meeting of the 10th board of directors on October 24, 2025, to discuss the proposal for issuing convertible bonds to unspecified targets [1] - For the first half of 2025, Hubei Yihua's revenue composition was as follows: chemical fertilizer manufacturing accounted for 39.93%, chemical products 36.08%, other industries 12.07%, and coal products 11.92% [1] - As of the report date, Hubei Yihua's market capitalization was 14.5 billion yuan [1] Group 2 - The Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year, indicating a robust market for biopharmaceuticals [1] - Despite the hot secondary market for biopharmaceuticals, the primary market is experiencing a cooling in fundraising activities [1]

Group 1 - The company Lihexing (SZ 301013) held its 15th meeting of the fourth board of directors on October 23, 2025, to discuss various proposals, including the completion of certain fundraising projects and the permanent allocation of surplus funds to working capital [1] - For the year 2024, the company's revenue composition is as follows: 74.42% from specialized equipment manufacturing and 25.58% from electronic components manufacturing [1] - As of the report date, Lihexing has a market capitalization of 6.7 billion yuan [1] Group 2 - The Chinese innovative pharmaceutical sector has generated $80 billion in overseas licensing deals this year, indicating a robust market for biopharmaceuticals [1] - Despite the hot secondary market for biopharmaceuticals, the primary market is experiencing a cooling in fundraising activities, as noted by investor Lu Gang [1]